Anti idh1 r132h h09 monoclonal antibody

Tissue sections were stained with an anti-ATRX polyclonal antibody (1: 300 dilution, ATLAS Antibodies AB, Bromma, Sweden), anti-GFAP (6F2) monoclonal antibody (1: 200 dilution, DAKO, Glostrup, Denmark), anti-IDH1 R132H (H09) monoclonal antibody (1:300 dilution, Dianova, Hamburg, Germany), anti-Ki67 (MIB-1) antibody (1:100 dilution, DAKO), anti-H3K27 M polyclonal antibody (1:700 Millipore, Temecula, USA), anti-p53 monoclonal antibody, DO-7 code M7001 (1:100 dilution, DAKO), anti-PHH3 antibody (1:100 dilution, Cell Marque, Rocklin, CA, USA) and anti-vimentin antibody (1:500, DAKO) (Supplementary Table 2). IHC staining was performed using a standard avidin–biotin-peroxidase method with a BenchMark ULTRA system (Roche Diagnostics, Indianapolis, US). The positive control was known positive tissue, and entrapped positive cells were used. For the negative control, the primary antibody was omitted.
ATRX gene mutations were scattered throughout exons and introns, making some sites difficult to capture using NGS. Since the initial version of our customized brain tumor panel could not detect full variants of ATRX mutations, we relied on ATRX IHC, but upgrade version of BTP panel could detect all the mutations.